<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03359538</url>
  </required_header>
  <id_info>
    <org_study_id>RAP-ALS</org_study_id>
    <nct_id>NCT03359538</nct_id>
  </id_info>
  <brief_title>Rapamycin Treatment for ALS</brief_title>
  <acronym>RAP-ALS</acronym>
  <official_title>Rapamycin (Sirolimus) Treatment for Amyotrophic Lateral Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Ospedaliero-Universitaria di Modena</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Modena and Reggio Emilia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Azienda Ospedaliero Universitaria Maggiore della Carita</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Turin, Italy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Azienda Ospedaliera Niguarda Cà Granda</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fondazione Salvatore Maugeri</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Padova</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Azienda Ospedaliero-Universitaria di Modena</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the last years research has pointed out potential mechanisms of pathogenesis in ALS
      including lack of degradation of abnormally accumulated proteins inside motor neurons, and an
      unbalanced function of the immune system leading to the prevalence of a neurotoxic function
      over neuroprotection. These two mechanisms contribute to ALS progression hence representing
      important therapeutic targets to modify disease expression.

      With a phase II clinical trial the investigators aim to study the biological response in ALS
      treated with Rapamycin, to obtain predictive information for a larger study.

      Eight Italian Centres will enroll 63 patients; treatment will be double blinded to patients
      and physicians, and will last 18 weeks.Follow up will be carried out for 36 months (total
      duration: 54 weeks).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase II randomized, double-blind, placebo-controlled, multicenter clinical trial
      for people with ALS.

      The aim is to study the biological and clinical effect of Rapamycin (in two different doses)
      in addition to Riluzole on ALS patients through comparison with patients treated with
      Riluzole and placebo.

      Rapamycin has been shown to enhance proteins degradation, and this has been associated with
      beneficial effects in models of neurodegeneration. Its immunomodulatory effects are also well
      established, notably the ability to suppress inflammatory neurotoxic responses mediated by T
      cells. As ALS is characterized by heterogeneous pathology and protein accumulation, some
      patients may respond to therapies that accelerate the clearance of abnormally accumulated
      proteic aggregates, while suppressing neurotoxic immune elements.

      Subjects will be enrolled in 3 groups of 21 subjects; treatment will be double blinded to
      patients and physicians, and will last 18 weeks. Active treatment will include oral Rapamycin
      at different doses: Rapamycin 1mg/m2/day or Rapamycin 2mg/m2/day. Rapamycin will be
      administered at fast, in the morning, once a day. Rapamycin levels will be measured (HPLC) to
      avoid toxicity (&gt;15 ng/ml), but treating neurologists will have no access to blood laboratory
      data. Dosages will be adjusted accordingly and sham adjustments will be done in the placebo
      Group too. Post-treatment follow up will be 36 weeks. Globally the study will lasts 24
      months. To monitor adverse events, examination and routine laboratory work (cell count,
      lipids and protein profile, kidney and liver function, C reactive protein) will be performed
      before taking Rapamycin/placebo. Non-routine laboratory studies include quantification and
      characterization of Tregs, lymphocytes phenotype, mTOR (mammilian target of rapamycin)
      downstream pathway activation in peripheral blood mononuclear cells (PBMC), inflammasome
      components in PBMC and proinflammatory cytokine production in monocytes, peripheral
      biomarkers. Cerebrospinal fluid (CSF) will be taken at baseline and at week 18 to measure
      neurofilaments and to dose Rapamycin to understand whether sufficient levels of Rapamycin can
      be found in the central nervous system (CNS).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 19, 2017</start_date>
  <completion_date type="Anticipated">September 19, 2019</completion_date>
  <primary_completion_date type="Anticipated">April 19, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>treatment double blinded to patients and physicians</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>T-reg number</measure>
    <time_frame>comparison between baseline and treatment end (week 18)</time_frame>
    <description>Proportion of patients exhibiting a positive response (considered as increase in Treg of at least 30%), comparing baseline and treatment end between Rapamycin and placebo arm</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of serious adverse events (SAEs) and AEs in placebo and treatment arms</measure>
    <time_frame>At week 18 and 54</time_frame>
    <description>Rapamycin safety and tolerability in a cohort of ALS patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rapamycin capacity to pass through blood brain barrier</measure>
    <time_frame>At week 18</time_frame>
    <description>HPLC-MS (mass spectrometry) dosage of Rapamycin in CSF in placebo and treatment arm will be performed at treatment end</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rapamycin efficacy in inhibiting Mtor pathway</measure>
    <time_frame>At week 8-18-30-54</time_frame>
    <description>Assessment of the phosphorylation of the S6 ribosomal protein (S6RP) comparing Rapamycin arms and placebo arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in activation and homing capabilities of different T, B, natural killer (NK) cell subpopulations</measure>
    <time_frame>At baseline and at week 8-18-30-54</time_frame>
    <description>Change from baseline to each time point (week 8, 18, 30, and 54) of the activation and homing capabilities of different T, B, NK cell subpopulations comparing Rapamycin arms and placebo arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in CSF neurofilaments</measure>
    <time_frame>Baseline and week 18</time_frame>
    <description>Changes from baseline to week 18 of the levels of neurofilaments in CSF in treatment and placebo arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in blood biomarkers</measure>
    <time_frame>Baseline, week 8-18-30-54</time_frame>
    <description>Changes from baseline to week 8-18-30.54 of the levels of neurofilaments and vitamin D in treatment and placebo arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rapamycin-induced changes in inflammatory status</measure>
    <time_frame>Baseline and week 8-18-30-54</time_frame>
    <description>Changes from baseline to each time point (week 8, 18, 30, and 54) in inflammatory status (cytokines and cells) (molecular analysis of the inflammasome system) comparing Rapamycin arms and placebo arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Amyotrophic Lateral Sclerosis functional rating scale (ALSFRS)-Revised</measure>
    <time_frame>Up to week 54</time_frame>
    <description>ALSFRS-R score changes from baseline to week 4, 8, 12, 18, 30, 42 and week 54 in treatment and placebo arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tracheostomy-free survival rate</measure>
    <time_frame>Up to week 54</time_frame>
    <description>Overall survival from randomization to date of death or tracheostomy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Forced vital capacity (FVC)</measure>
    <time_frame>Up to week 54</time_frame>
    <description>Changes in FVC score from baseline to week 4, 8, 12, 18, 30, 42, 54 in treatment and placebo arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life</measure>
    <time_frame>From baseline to week 8, 18, 30 and week 54</time_frame>
    <description>Changes in Amyotrophic Lateral Sclerosis Assessment Questionnaire (ALSAQ-40) from baseline to week 8, 18, 30 and week 54, in placebo and treatment arms</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">63</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients assigned to this arm will take Riluzole as usual + placebo tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rapamycin 1 mg/m2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients assigned to this arm will take Riluzole as usual + tablets corresponding to a Rapamycin dose of 1 mg/m2/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rapamycin 2 mg/m2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients assigned to this arm will take Riluzole as usual + tablets corresponding to a Rapamycin dose of 2 mg/m2/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rapamycin</intervention_name>
    <description>tablets containing Rapamycin/placebo will be administered based on body surface area and adjusted taking into consideration plasma rapamycin dosage</description>
    <arm_group_label>Rapamycin 1 mg/m2</arm_group_label>
    <arm_group_label>Rapamycin 2 mg/m2</arm_group_label>
    <other_name>Rapamune</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>tablets containing Rapamycin/placebo will be administered based on body surface area and adjusted taking into consideration plasma rapamycin dosage</description>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_label>Rapamycin 1 mg/m2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Patient diagnosed with a laboratory supported , clinically &quot;probable&quot; or &quot;definite&quot;
             amyotrophic lateral sclerosis according to the Revised El Escorial criteria (Brooks,
             2000)

          -  Familial or sporadic ALS

          -  Female or male patients aged between 18 and 75 years old

          -  Disease duration from symptoms onset no longer than 18 months at the screening visit

          -  Patient treated with a stable dose of Riluzole (100 mg/day) for at least 30 days prior
             to screening

          -  Patients with a weight &gt; 50 kg and a BMI ≥18

          -  Patient with a FVC ≥ 70 % predicted normal value for gender, height, and age at the
             screening visit

          -  Patient able and willing to comply with study procedures as per protocol

          -  Patient able to understand, and capable of providing informed consent at screening
             visit prior to any protocol-specific procedures

          -  Use of effective contraception both for males and females

        Exclusion Criteria:

          -  Prior use of Sirolimus

          -  Prior allergy/sensitivity to Sirolimus or macrolides

          -  Any medical disorder that would make immunosuppression contraindicated, including but
             not limited to, acute infections requiring antibiotics, patients with known diagnosis
             of HIV, tuberculosis, hepatitis B or C infection or history of malignancy

          -  Severe comorbidities (heart, renal, liver failure), autoimmune diseases or any type of
             interstitial lung disease

          -  White blood cells&lt;4,000/mm³, platelets count&lt;100,000/mm³, hematocrit&lt;30%

          -  Patient who underwent non invasive ventilation, tracheotomy and /or gastrostomy

          -  Women who are pregnant or breastfeeding

          -  Participation in pharmacological studies within the last 30 days before screening

          -  Patients with known superoxide dismutase 1 (SOD1) mutation or with familial ALS and a
             family member carrying SOD1 mutation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jessica Mandrioli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Azienda Ospedaliero-Universitaria di Modena</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jessica Mandrioli, MD</last_name>
    <phone>+300593961700</phone>
    <email>j.mandrioli@ausl.mo.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centro Sla, Irccs A.O.U. S.Martino Ist, Genova</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Claudia Caponnetto, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Clinico Nemo, Fondazione Serena Onlus, Milano</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christian Lunetta, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Sla, Irccs Fondazione Salvatore Maugeri, Milano</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kalliopi Marinou, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Sla, Irccs Istituto Carlo Besta, Milano</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eleonora Dalla Bella, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Sla, Ospedale Civile S. Agostino Estense, A.O.U. Modena</name>
      <address>
        <city>Modena</city>
        <zip>41126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Mandrioli, MD</last_name>
      <phone>+390593961722</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Sla, A.O.U. Maggiore Della Carita', Novara</name>
      <address>
        <city>Novara</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Letizia Mazzini, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Sla, Universita' Di Padova</name>
      <address>
        <city>Padova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gianni Sorarù, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Sla, Universita' Di Torino</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Adriano Chiò, Prof.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Barmada SJ, Serio A, Arjun A, Bilican B, Daub A, Ando DM, Tsvetkov A, Pleiss M, Li X, Peisach D, Shaw C, Chandran S, Finkbeiner S. Autophagy induction enhances TDP43 turnover and survival in neuronal ALS models. Nat Chem Biol. 2014 Aug;10(8):677-85. doi: 10.1038/nchembio.1563. Epub 2014 Jun 29.</citation>
    <PMID>24974230</PMID>
  </reference>
  <reference>
    <citation>Beers DR, Henkel JS, Zhao W, Wang J, Huang A, Wen S, Liao B, Appel SH. Endogenous regulatory T lymphocytes ameliorate amyotrophic lateral sclerosis in mice and correlate with disease progression in patients with amyotrophic lateral sclerosis. Brain. 2011 May;134(Pt 5):1293-314. doi: 10.1093/brain/awr074.</citation>
    <PMID>21596768</PMID>
  </reference>
  <reference>
    <citation>Buchan JR, Kolaitis RM, Taylor JP, Parker R. Eukaryotic stress granules are cleared by autophagy and Cdc48/VCP function. Cell. 2013 Jun 20;153(7):1461-74. doi: 10.1016/j.cell.2013.05.037.</citation>
    <PMID>23791177</PMID>
  </reference>
  <reference>
    <citation>Caccamo A, Majumder S, Deng JJ, Bai Y, Thornton FB, Oddo S. Rapamycin rescues TDP-43 mislocalization and the associated low molecular mass neurofilament instability. J Biol Chem. 2009 Oct 2;284(40):27416-24. doi: 10.1074/jbc.M109.031278. Epub 2009 Aug 3.</citation>
    <PMID>19651785</PMID>
  </reference>
  <reference>
    <citation>Chiò A, Hammond ER, Mora G, Bonito V, Filippini G. Development and evaluation of a clinical staging system for amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2015 Jan;86(1):38-44. doi: 10.1136/jnnp-2013-306589. Epub 2013 Dec 13.</citation>
    <PMID>24336810</PMID>
  </reference>
  <reference>
    <citation>Cirulli ET, Lasseigne BN, Petrovski S, Sapp PC, Dion PA, Leblond CS, Couthouis J, Lu YF, Wang Q, Krueger BJ, Ren Z, Keebler J, Han Y, Levy SE, Boone BE, Wimbish JR, Waite LL, Jones AL, Carulli JP, Day-Williams AG, Staropoli JF, Xin WW, Chesi A, Raphael AR, McKenna-Yasek D, Cady J, Vianney de Jong JM, Kenna KP, Smith BN, Topp S, Miller J, Gkazi A; FALS Sequencing Consortium, Al-Chalabi A, van den Berg LH, Veldink J, Silani V, Ticozzi N, Shaw CE, Baloh RH, Appel S, Simpson E, Lagier-Tourenne C, Pulst SM, Gibson S, Trojanowski JQ, Elman L, McCluskey L, Grossman M, Shneider NA, Chung WK, Ravits JM, Glass JD, Sims KB, Van Deerlin VM, Maniatis T, Hayes SD, Ordureau A, Swarup S, Landers J, Baas F, Allen AS, Bedlack RS, Harper JW, Gitler AD, Rouleau GA, Brown R, Harms MB, Cooper GM, Harris T, Myers RM, Goldstein DB. Exome sequencing in amyotrophic lateral sclerosis identifies risk genes and pathways. Science. 2015 Mar 27;347(6229):1436-41. doi: 10.1126/science.aaa3650. Epub 2015 Feb 19.</citation>
    <PMID>25700176</PMID>
  </reference>
  <reference>
    <citation>Cloughesy TF, Yoshimoto K, Nghiemphu P, Brown K, Dang J, Zhu S, Hsueh T, Chen Y, Wang W, Youngkin D, Liau L, Martin N, Becker D, Bergsneider M, Lai A, Green R, Oglesby T, Koleto M, Trent J, Horvath S, Mischel PS, Mellinghoff IK, Sawyers CL. Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med. 2008 Jan 22;5(1):e8. doi: 10.1371/journal.pmed.0050008.</citation>
    <PMID>18215105</PMID>
  </reference>
  <reference>
    <citation>Deivasigamani S, Verma HK, Ueda R, Ratnaparkhi A, Ratnaparkhi GS. A genetic screen identifies Tor as an interactor of VAPB in a Drosophila model of amyotrophic lateral sclerosis. Biol Open. 2014 Oct 31;3(11):1127-38. doi: 10.1242/bio.201410066.</citation>
    <PMID>25361581</PMID>
  </reference>
  <reference>
    <citation>Harrison DE, Strong R, Sharp ZD, Nelson JF, Astle CM, Flurkey K, Nadon NL, Wilkinson JE, Frenkel K, Carter CS, Pahor M, Javors MA, Fernandez E, Miller RA. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature. 2009 Jul 16;460(7253):392-5. doi: 10.1038/nature08221. Epub 2009 Jul 8.</citation>
    <PMID>19587680</PMID>
  </reference>
  <reference>
    <citation>Kimura F, Fujimura C, Ishida S, Nakajima H, Furutama D, Uehara H, Shinoda K, Sugino M, Hanafusa T. Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS. Neurology. 2006 Jan 24;66(2):265-7.</citation>
    <PMID>16434671</PMID>
  </reference>
  <reference>
    <citation>Komatsu M, Waguri S, Chiba T, Murata S, Iwata J, Tanida I, Ueno T, Koike M, Uchiyama Y, Kominami E, Tanaka K. Loss of autophagy in the central nervous system causes neurodegeneration in mice. Nature. 2006 Jun 15;441(7095):880-4. Epub 2006 Apr 19.</citation>
    <PMID>16625205</PMID>
  </reference>
  <reference>
    <citation>Lattante S, de Calbiac H, Le Ber I, Brice A, Ciura S, Kabashi E. Sqstm1 knock-down causes a locomotor phenotype ameliorated by rapamycin in a zebrafish model of ALS/FTLD. Hum Mol Genet. 2015 Mar 15;24(6):1682-90. doi: 10.1093/hmg/ddu580. Epub 2014 Nov 19.</citation>
    <PMID>25410659</PMID>
  </reference>
  <reference>
    <citation>Lipton JO, Sahin M. The neurology of mTOR. Neuron. 2014 Oct 22;84(2):275-91. doi: 10.1016/j.neuron.2014.09.034. Epub 2014 Oct 22. Review.</citation>
    <PMID>25374355</PMID>
  </reference>
  <reference>
    <citation>Mantovani S, Garbelli S, Pasini A, Alimonti D, Perotti C, Melazzini M, Bendotti C, Mora G. Immune system alterations in sporadic amyotrophic lateral sclerosis patients suggest an ongoing neuroinflammatory process. J Neuroimmunol. 2009 May 29;210(1-2):73-9. doi: 10.1016/j.jneuroim.2009.02.012.</citation>
    <PMID>19307024</PMID>
  </reference>
  <reference>
    <citation>Ravikumar B, Vacher C, Berger Z, Davies JE, Luo S, Oroz LG, Scaravilli F, Easton DF, Duden R, O'Kane CJ, Rubinsztein DC. Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat Genet. 2004 Jun;36(6):585-95. Epub 2004 May 16.</citation>
    <PMID>15146184</PMID>
  </reference>
  <reference>
    <citation>Shi CS, Shenderov K, Huang NN, Kabat J, Abu-Asab M, Fitzgerald KA, Sher A, Kehrl JH. Activation of autophagy by inflammatory signals limits IL-1β production by targeting ubiquitinated inflammasomes for destruction. Nat Immunol. 2012 Jan 29;13(3):255-63. doi: 10.1038/ni.2215.</citation>
    <PMID>22286270</PMID>
  </reference>
  <reference>
    <citation>Staats KA, Hernandez S, Schönefeldt S, Bento-Abreu A, Dooley J, Van Damme P, Liston A, Robberecht W, Van Den Bosch L. Rapamycin increases survival in ALS mice lacking mature lymphocytes. Mol Neurodegener. 2013 Sep 11;8:31. doi: 10.1186/1750-1326-8-31.</citation>
    <PMID>24025516</PMID>
  </reference>
  <reference>
    <citation>Thomas M, Alegre-Abarrategui J, Wade-Martins R. RNA dysfunction and aggrephagy at the centre of an amyotrophic lateral sclerosis/frontotemporal dementia disease continuum. Brain. 2013 May;136(Pt 5):1345-60. doi: 10.1093/brain/awt030. Epub 2013 Mar 9. Review.</citation>
    <PMID>23474849</PMID>
  </reference>
  <reference>
    <citation>Wang IF, Guo BS, Liu YC, Wu CC, Yang CH, Tsai KJ, Shen CK. Autophagy activators rescue and alleviate pathogenesis of a mouse model with proteinopathies of the TAR DNA-binding protein 43. Proc Natl Acad Sci U S A. 2012 Sep 11;109(37):15024-9. doi: 10.1073/pnas.1206362109. Epub 2012 Aug 29.</citation>
    <PMID>22932872</PMID>
  </reference>
  <reference>
    <citation>Zhang X, Li L, Chen S, Yang D, Wang Y, Zhang X, Wang Z, Le W. Rapamycin treatment augments motor neuron degeneration in SOD1(G93A) mouse model of amyotrophic lateral sclerosis. Autophagy. 2011 Apr;7(4):412-25. Epub 2011 Apr 1.</citation>
    <PMID>21193837</PMID>
  </reference>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 8, 2017</study_first_submitted>
  <study_first_submitted_qc>November 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 2, 2017</study_first_posted>
  <last_update_submitted>December 1, 2017</last_update_submitted>
  <last_update_submitted_qc>December 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Azienda Ospedaliero-Universitaria di Modena</investigator_affiliation>
    <investigator_full_name>Jessica Mandrioli</investigator_full_name>
    <investigator_title>MD, PI</investigator_title>
  </responsible_party>
  <keyword>Amyotrophic Lateral Sclerosis</keyword>
  <keyword>Motor Neuron Disease</keyword>
  <keyword>Rapamycin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

